Tirzepatide is a prescription medication that activates two hormone receptors — glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) — making it what’s known as a dual agonist. It is used in clinically supervised contexts for type 2 diabetes management and medically guided weight care. Like all GLP-1 class medications, it is available by prescription only and requires evaluation by a licensed healthcare provider.

Tirzepatide is one of the newer prescription medications in the GLP-1 class, and it differs from other medications in this category in an important way: it activates two hormone receptors rather than one. This dual mechanism has made it a subject of significant scientific interest, and it has been studied in clinical trials focused on both type 2 diabetes and weight management.

As a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide mimics two gut hormones that the body naturally produces after eating. By activating both receptors, it engages two separate but related pathways involved in metabolism, appetite, and blood sugar regulation.

Diccover what tirzepatide is, how it works, what it is used for, what a compounded version means, and what to consider before exploring tirzepatide care with a licensed provider.

What is tirzepatide?

Tirzepatide is an active pharmaceutical ingredient classified as a dual GLP-1 and GIP receptor agonist. This means it is designed to activate two types of receptors that the body uses to regulate metabolism after eating.

GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are both incretin hormones — hormones released by the gut in response to food intake that influence insulin secretion, blood sugar management, and satiety signaling. Tirzepatide mimics both of these hormones simultaneously.¹

Tirzepatide is administered as a subcutaneous (under the skin) injection, typically once weekly. It is started at a low dose and increased gradually over time through a titration schedule established by the prescribing provider.

How does tirzepatide work?

Tirzepatide’s dual mechanism means it engages two distinct but related hormonal pathways at the same time. Here is how each receptor contributes.

1. GLP-1 receptor activation

The GLP-1 receptor is found in the brain, gut, pancreas, and other tissues. It is part of the body’s natural system for regulating blood sugar, digestion, and appetite signaling after eating. Tirzepatide activates this receptor as one component of its dual mechanism.¹

2. GIP receptor activation

The GIP receptor is found in the pancreas, adipose (fat) tissue, and the brain. GIP receptor activation enhances insulin secretion in a glucose-dependent manner and may influence how the body processes and stores fat. Researchers are still studying the full scope of GIP’s role in metabolism.¹

3. Combined metabolic effects

By activating both receptors, tirzepatide engages two separate hormonal pathways involved in blood sugar regulation, digestive slowing, and satiety. The combined action of GLP-1 and GIP receptor agonism has been the subject of ongoing clinical research.¹

4. Dose titration

Tirzepatide is started at a low dose and titrated upward over several weeks or months to a maintenance dose. This process allows the body to adjust gradually and allows the provider to assess how the medication is being tolerated.

What is tirzepatide used for?

Tirzepatide’s clinical uses depend on the specific approved indications for a given formulation and dose, as determined by the prescribing provider.

Common contexts in which licensed providers may consider tirzepatide include:

• Type 2 diabetes management — supporting blood sugar control as part of a comprehensive treatment plan that includes lifestyle changes
• Medically supervised weight management — in adults whose weight-related health status may make prescription treatment appropriate, based on a provider’s clinical evaluation.

A licensed provider evaluates the patient’s health history, current medications, and goals to determine whether tirzepatide may be appropriate and which formulation to prescribe.

What is compounded tirzepatide?

Compounded tirzepatide is a form of tirzepatide prepared by a state-licensed compounding pharmacy or federally registered outsourcing facility. It is not manufactured by a pharmaceutical company as a branded drug product.

Compounded tirzepatide is not FDA-approved and has not been evaluated by the FDA for safety, efficacy, or quality.² It is not the same as any brand-name tirzepatide medication, and it is not a generic. A licensed prescriber determines whether a compounded version is appropriate for an individual patient based on that patient’s specific clinical needs.

Compounded tirzepatide is available by prescription only and requires a full health evaluation by a licensed healthcare provider before a prescription may be issued.

What should you discuss with a provider before starting tirzepatide?

Before prescribing tirzepatide, a licensed provider will review several areas of a patient’s health history. These typically include:

• Personal and family medical history, including any history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
• Current medications, including insulin or other diabetes medications, which may require dosage adjustments
• Kidney, gallbladder, or pancreatic health history
• Whether the patient is pregnant, breastfeeding, or planning to become pregnant
• Prior weight management history and relevant treatment goals

Not everyone is a suitable candidate for tirzepatide. A licensed provider is the appropriate person to evaluate whether tirzepatide care is right for an individual patient.

How LumiMeds Can Help

LumiMeds connects patients with licensed providers who can review their health history and treatment goals to determine whether prescription tirzepatide care may be medically appropriate. If prescribed, compounded tirzepatide may be fulfilled through state-licensed compounding pharmacies and shipped directly to you.

Start your online assessment to see if you may be a candidate for tirzepatide care through LumiMeds.

Key Takeaways

• Tirzepatide is a dual GLP-1 and GIP receptor agonist — a prescription medication that mimics two gut hormones the body naturally produces after eating.
• Its dual mechanism engages two separate hormonal pathways involved in blood sugar regulation, digestion, and satiety signaling.
• Tirzepatide is used in clinically supervised contexts for type 2 diabetes, medically guided weight management, and in some cases obstructive sleep apnea, as determined by a licensed provider.
• Compounded tirzepatide is not FDA-approved and is not the same as any brand-name drug. It requires a prescription based on an individual clinical evaluation.
• A licensed provider determines whether tirzepatide is medically appropriate based on a review of health history, current medications, and treatment goals.

FAQs

What makes tirzepatide different from other GLP-1 medications?

Most GLP-1 medications activate only the GLP-1 receptor. Tirzepatide is a dual agonist — it activates both the GLP-1 and GIP receptors simultaneously. This two-receptor approach engages additional hormonal pathways compared to GLP-1-only medications. A licensed provider can help evaluate whether tirzepatide or another GLP-1 medication may be appropriate based on individual health needs.

Is tirzepatide the same as Mounjaro or Zepbound?

Tirzepatide is the active ingredient in brand-name medications that have been approved for specific indications. Mounjaro® is a registered trademark of Eli Lilly. Zepbound® is a registered trademark of Eli Lilly. LumiMeds is not affiliated with or endorsed by Eli Lilly. Compounded tirzepatide is not the same as these brand-name products and is not a generic.

Does tirzepatide require a prescription?

Yes. Tirzepatide is a prescription medication in all of its forms, including compounded versions. A licensed healthcare provider must evaluate the patient and determine that tirzepatide is medically appropriate before a prescription can be issued.

How is tirzepatide administered?

Tirzepatide is administered as a subcutaneous (under the skin) injection, typically once weekly. It is started at a low dose and increased gradually through a titration schedule established by the prescribing provider.

What is the difference between tirzepatide and semaglutide?

Both are prescription medications used in the context of type 2 diabetes management and medically supervised weight care. The key difference is that semaglutide activates the GLP-1 receptor only, while tirzepatide activates both the GLP-1 and GIP receptors. A licensed provider can help determine which option may be appropriate for an individual patient based on their health history and goals.

Can you get tirzepatide online?

Through a telehealth provider, patients can complete a health evaluation with a licensed provider online. If the provider determines that tirzepatide is medically appropriate, a prescription may be issued and compounded medication may be fulfilled through a state-licensed compounding pharmacy and shipped to the patient.

Compounded medications are not FDA-approved and have not been evaluated for safety and effectiveness by the FDA. Compounded medications are not brand-name drugs nor are they considered “generics.” Compounded medications are prepared by state-licensed compounding pharmacies or federally registered outsourcing facilities.

Payment does not guarantee the writing or dispensing of a prescription. A licensed provider will determine whether treatment is medically appropriate based on individual health history and needs.

This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a licensed healthcare provider with any questions you may have regarding a medical condition or treatment.

Sources

1. Frias, J. P., et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” New England Journal of Medicine. https://www.nejm.org/doi/10.1056/NEJMoa2107519
2. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers